X

Drug Profile

Research programme: antibacterials - Essential Therapeutics/Johnson & Johnson

Latest Information Update: 29 Aug 2007

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Essential Therapeutics [CEASED]
Developer Essential Therapeutics [CEASED]; Johnson & Johnson Pharmaceutical Research & Development LLC; Ortho-McNeil
Class
Mechanism of Action Cell wall inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Respiratory tract infections

Most Recent Events

04 Oct 2004 Essential Therapeutics has closed down
19 Jan 2001 Preclinical development for Respiratory tract infections in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com